TD Cowen raises Axsome stock price target on strong Q1 results

Axsome Therapeutics reported Q1 revenue of $191 million, up 57% year over year and slightly above the $188 million consensus, while Auvelity sales reached $153 million versus $148 million expected. TD Cowen raised its price target to $275 from $255, citing stronger commercial execution and a higher atypical depression peak-sales estimate of $1.75 billion. The article also notes a separate Q1 2026 EPS miss of -$1.26 versus -$0.83 and revenue of $191.2 million versus $193.46 million expected, creating a mixed but still constructive setup for the stock.

Analysis

AXSM is transitioning from a single-asset launch story into a broader commercial durability story, and that matters more than the headline beat. When a company with high gross margins keeps compounding revenue at this pace, the market usually starts paying for optionality in follow-on indications rather than just current-year sales; that tends to compress discount rates, not just expand revenue multiples. The key second-order effect is that stronger uptake in one use case lowers perceived execution risk for the next one, which can re-rate the entire pipeline rather than just one product.

The near-term upside is still mostly about sentiment and positioning, not fundamentals. A higher sell-side peak-sales estimate can act as a catalyst for multiple expansion over the next 1-3 months, but the stock is vulnerable if the June launch data do not confirm broad prescriber adoption quickly. The market is likely underestimating how much of the thesis depends on primary-care conversion velocity; if specialty enthusiasm fails to translate into refill behavior, the current optimism can unwind fast.

The contrarian angle is that the market may be overpaying for a clean launch narrative while underweighting competitive and reimbursement friction. In CNS/depression, payer controls and step-editing can delay the real revenue inflection by quarters even when physician sentiment is strong, so the risk/reward is asymmetric only if management can demonstrate rapid access normalization. On the other hand, if launch metrics improve through summer, the stock could re-rate into a multi-quarter growth compounder rather than a one-event earnings winner.

For now, the best setup is to treat this as a catalyst-driven long with defined downside, not a chase. The stock can work higher on estimate revisions, but the path likely includes volatility around launch data and any commentary on payer mix. That makes options and relative-value expressions more attractive than outright size for most portfolios.

Key Decisions for Investors

• Long AXSM into the June atypical depression launch catalyst; target a 2-3 month horizon and size for high volatility, with upside tied to evidence of rapid prescriber conversion and access expansion.
• Buy AXSM call spreads 3-6 months out rather than common stock if chasing the revision cycle; this captures the multiple expansion thesis while defining downside if launch execution disappoints.
• Use pullbacks toward post-earnings support to add, but cut quickly if June launch commentary indicates payer friction or slow refill trends; that would likely compress the premium within 4-8 weeks.
• Pair AXSM long against a slower-growth CNS peer basket to isolate idiosyncratic launch upside; this reduces market beta and monetizes the difference between commercial execution and perception.
• If AXSM rallies aggressively on estimate revisions alone, take partial profits into the move and wait for hard launch metrics before re-adding; the risk/reward worsens once the story becomes consensus.